profile following atorvastatin treatment. Results: Atorvastatin treatment of PC3 cells for 24 h increased the expression of GFP-LC3-II by >25% and expression continued for >72 h, while apoptosis was not significantly induced within this time period. Four genes associated with the autophagy machinery were also significantly upregulated. Conclusions: In the presence of atorvastatin, autophagy may be unable to abrogate cell damage and may therefore contribute to cellular dysfunction, leading to autophagic/ type II programmed cell death. In response to atorvastatin treatment, the expression of genes involved in autophagic mediating pathways may have a role in tumor suppression.
AB159. A C/T germline singlenucleotide polymorphism in the PARP1 gene is associated with survival of bladder cancer in a Gansu population-based study Kaplan-Meier analysis estimates a decreasing OS (P=0.020) between CC, CT and TT genotype patients, survival curves were calculated for overall according to the PARP1 genotypes and between C-allele and T-allele. However, patients with TT genotype had significantly shorter survival time compared with the (CT + CC) genotype patients. In multivariate analysis, revealed that pathological classification (HR 4.183, ; P=0.025), smoking status (HR 6.202, 1.014-37.914; P=0.048) and recurrence (HR 32.529, 3.397-311.535; P=0.003) were found to be a strong independent prognosticator with marked increased risk for poor OS in different genotype. Despite the close correlation between PARP1-SNP and survival in univariate analysis, there was no significant difference in the probabilities of overall survival between the genotypes (P=0.832) in this study cohort. Conclusions: Analysis of genotypes and clinical data for bladder cancer patients indicates that the PARP1 rs1805415 genotype may be a useful prognostic genetic marker for bladder cancer. AB160. Association of nineteen polymorphisms from seven DNA repair genes and the risk for bladder cancer in China Objective: Balance of DNA damage and proper repair plays an important role in progression of bladder cancer. Here we aimed to assess the associations of nineteen polymorphisms from seven DNA repair-associated genes (PRAP1, OGG1, APEX1, MUTYH, XRCC1, XRCC2 and XRCC3) and their interactions with bladder cancer in a Han Chinese population. Methods: A case-control study including 227 bladder cancer patients and 260 healthy controls was conducted. A chip-based TaqMan genotyping was performed for the candidate genes. Results: APEX1 rs3136817, MUTYH rs3219493, three SNPs (rs3213356, rs2023614 and rs1799782) in XRCC1, and two SNPs (rs1799794 and rs861530) in XRCC3 showed significant associations with the risk of bladder cancer. After the Bonferroni correction, these associations were still significant. In haplotype analysis, Haplotype GT in APEX1 had a higher frequency in cases than in controls (P=0.003). Haplotype GGGTC in XRCC1 also had a higher frequency in cases than in controls (P=0.002), whereas haplotypes GCGCC and GCGTT in XRCC1 had lower frequencies in cases (P=0.001; P=0.005, respectively). Haplotype CCC in MUTYH and TTTAC in XRCC3 had a lower frequency in cases (P=0.004; P=0.009, respectively). In further interaction analysis, the five locus model including rs3218454, rs1799794, rs861537, rs861531 and rs861530 emerged as the best multifactor dimensionality reduction (MDR) model in homologous recombination repair (HRR) genes with the maximal testing accuracy of 0.701 and the maximal crossvalidation consistency of 10 out of 10 (P=0.001). Conclusions: Our findings provide evidence that polymorphisms of DNA repair genes may affect the risk of bladder cancer and those two SNPs (rs1799794 and rs861530) in XRCC3 gene might exert effects on the development of bladder cancer in a northwest Chinese population in both independent and interaction analyses. 
